Evidence map›Paper›PMID 42089990›Full record

ReviewAbdominal radiology (New York)2026

Recent developments and prospects in locoregional therapy of hepatocellular carcinoma.

Lauren Park, Anirudh Maddali, David C Madoff, Hooman Yarmohammadi, Emil I Cohen, Neil K Jain, Nima Kokabi, Christos Georgiades, Armeen Mahvash, Peiman Habibollahi and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lauren ParkDivision of Vascular and Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Anirudh MaddaliGeorgetown University School of Medicine, Washington, D.C., USA.
David C MadoffDepartment of Radiology and Biomedical Imaging, Section of Interventional Radiology, Yale University School of Medicine, New Haven, CT, USA.
Hooman YarmohammadiDivision of Interventional Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Emil I CohenGeorgetown University School of Medicine, Washington, D.C., USA.
Neil K JainDivision of Vascular and Interventional Radiology, Department of Radiology, MedStar Georgetown University Hospital, Washington, D.C., USA.
Nima KokabiDepartment of Radiology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Christos GeorgiadesDivision of Vascular and Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Armeen MahvashDepartment of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peiman HabibollahiDepartment of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nariman NezamiGeorgetown University School of Medicine, Washington, D.C., USA. dr.nezami@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This invited review discusses recent advancements and prospects in locoregional therapy (LRT) for hepatocellular carcinoma (HCC), a leading cause of cancer mortality globally. The epidemiology of HCC is shifting toward nonviral etiologies, prompting a focus on early surveillance and personalized treatment approaches. Updated international guidelines, such as the Barcelona Clinic Liver Cancer (BCLC) staging system, American Association for Study of Liver Disease (AASLD) guideline, and European Association for the Study of the Liver (EASL) now recognize LRT-including transarterial embolization, ablation, and radiotherapy-as cornerstone therapies in curative and downstaging strategies for HCC at multiple stages. The article reviews novel transarterial and ablative technologies, including advanced dosimetry for radioembolization, innovative embolic agents, and emerging nonthermal ablation modalities like irreversible electroporation and pulsed electric field ablation, all aimed at increasing precision, local delivery, minimizing systemic exposure. Additionally, combination approaches integrating LRT with immunotherapy are highlighted, reflecting the evolving understanding of HCC's tumor-immune microenvironment. Progress in robotic guidance, fusion imaging, and imageable radioembolics is also explored. Ongoing and future clinical trials will further define the optimal use of these evolving modalities. Overall, LRT continues to expand as a minimally invasive, indispensable backbone in multidisciplinary HCC management.

Indexed as

Combination therapyHepatocellular carcinomaLocoregional therapyPercutaneous interventionTransarterial therapy

Identifiers

PMID42089990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.